Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 57.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,438 shares of the company’s stock after selling 59,567 shares during the period. Los Angeles Capital Management LLC’s holdings in Stoke Therapeutics were worth $479,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of STOK. China Universal Asset Management Co. Ltd. bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $124,000. Intech Investment Management LLC bought a new position in Stoke Therapeutics in the third quarter worth about $160,000. Mesirow Financial Investment Management Inc. acquired a new position in Stoke Therapeutics in the third quarter valued at approximately $192,000. Rhumbline Advisers grew its holdings in shares of Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after purchasing an additional 2,787 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after purchasing an additional 71,647 shares during the period.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on STOK. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. HC Wainwright boosted their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $23.00.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 13,945 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the transaction, the insider now owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the sale, the general counsel now owns 21,476 shares of the company’s stock, valued at $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 52,849 shares of company stock valued at $688,721. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Stock Down 5.7 %

STOK stock opened at $7.40 on Tuesday. The company has a 50-day simple moving average of $10.11 and a 200 day simple moving average of $12.00. The company has a market capitalization of $391.96 million, a P/E ratio of -3.52 and a beta of 0.95. Stoke Therapeutics, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $17.58.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.